— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.
— Government contract revenue was $413,458 for the three months ended December 31, 2019.
— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.
— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.
— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.
Most Popular
Important takeaways from Paychex’s (PAYX) Q2 2025 earnings report
Paychex Inc. (NASDAQ: PAYX), a leading provider of human resources and payroll services, reported better-than-expected revenue and profit for the second quarter of fiscal 2025, sending the stock higher soon
Lamb Weston’s (LW) challenges may not end soon, a few points to note
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) turned red in mid-day trade on Friday. The stock has dropped 19% in the past one month. The company delivered disappointing results
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
